Liquid Biopsies: Handle With Care
DOI:
https://doi.org/10.17140/PLMOJ-1-102Abstract
Possibly the first mention of the term ‘liquid biopsy’ (as it is understood today) in
the scientific literature appears in a report about the 7th International Symposium on Minimal
Residual Cancer (ISMRC) held in Athens, Greece in 2009.1 The symposium had focused on,
among other things, Circulating Tumor Cells (CTCs) and their relationship to Cancer Stem
Cells (CSCs). In that symposium, it was reported that Howard Scher of Memorial Sloan-Kettering
Cancer Center described the application of CTCs in the evaluation of therapies directed
at castration-resistant prostate cancer, as a ‘liquid biopsy’. With time, the term has slowly
gained popularity: as of 24th January, 2016, 237 PubMed articles have the term ‘liquid biopsy’
in the title or the abstract.
References
Lianidou ES1, Mavroudis D, Sotiropoulou G, Agelaki S, Pan-tel K. What’s new on circulating tumor cells? a meeting report. Breast Cancer Res. 2010; 12(4): 307. doi: 10.1186/bcr2601
Kim VN. MicroRNA biogenesis: coordinated cropping and di-cing. Nat Rev Mol Cell Biol. 2005; 6(5): 376-385. doi: 10.1038/ nrm1644
Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002; 99(24): 15524-15529. doi: 10.1073/pnas.242606799
Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting mi-croRNAs for cancer therapy. Nat Rev Cancer. 2011; 11(12): 849- 864. doi: 10.1038/nrc3166
Marzese DM, Hirose H, Hoon DS. Diagnostic and pro-gnostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn. 2013; 13(8): 827-844. doi: 10.1586/14737159.2013.845088
Hoshimoto S, Shingai T, Morton DL, et al. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol. 2012; 30(31): 3819-3826. doi: 10.1200/JCO.2011.40.0887
Regalado A. The great cancer test experiment. Website: http:// www.technologyreview.com/news/538646/why-liquid-biop-sies-in-cancer-treatment-are-still-experimental/ 2015; Accessed 2016.
US Food and Drug Administration. Available at: http://www. fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/ UCM464092.pdf 2015; Accessed October 27, 2015.
Dawson SJ, Tsui DWY, Murtaza M, et al. Analysis of circu-lating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13): 1199-1209. doi: 10.1056/NEJMoa1213261
Burke A. Foundation medicine: personalizing cancer drugs. Website: http://www.technologyreview.com/featuredstory/4269 87/foundation-medicine-personalizing-cancer-drugs/ 2012; Ac-cessed 2016.
Regalado A. The great cancer test experiment. Biomedi-cine News. Website: http://www.technologyreview.com/news/ 538646/why-liquid-biopsies-in-cancer-treatment-are-still-expe-rimental/ 2015; Accessed 2016.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pathology and Laboratory Medicine (PLM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.